Smooth muscle tumour of uncertain malignant potential: Difference between revisions
Jump to navigation
Jump to search
split out |
mNo edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Smooth muscle tumour of uncertain malignant potential''', abbreviated '''STUMP''' is smooth muscle lesion in which the behaviour (benign vs. malignant) cannot be ascertained with certainty. | '''Smooth muscle tumour of uncertain malignant potential''', abbreviated '''STUMP''', is smooth muscle lesion in which the behaviour (benign vs. malignant) cannot be ascertained with certainty. | ||
This entity should '''not''' be confused with the [[Prostatic stromal tumour of uncertain malignant potential|prostatic stromal tumour]] that is occasionally abbreviated ''STUMP''. | |||
==General== | ==General== | ||
*Like ''[[ASAP]]'' and ''[[ASCUS]]'' - a [[waffle diagnosis|waffle category]]... when one isn't sure it is a ''leiomyoma'' vs. ''leiomyosarcoma''. | *Like ''[[ASAP]]'' and ''[[ASCUS]]'' - a [[waffle diagnosis|waffle category]]... when one isn't sure it is a ''[[leiomyoma]]'' vs. ''[[leiomyosarcoma]]''. | ||
*Clinical behaviour in uterus: usually benign.<ref name=pmid19417585>{{cite journal |author=Ip PP, Cheung AN, Clement PB |title=Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases |journal=Am. J. Surg. Pathol. |volume=33 |issue=7 |pages=992–1005 |year=2009 |month=July |pmid=19417585 |doi=10.1097/PAS.0b013e3181a02d1c |url=}}</ref> | *Clinical behaviour in uterus: usually benign.<ref name=pmid19417585>{{cite journal |author=Ip PP, Cheung AN, Clement PB |title=Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases |journal=Am. J. Surg. Pathol. |volume=33 |issue=7 |pages=992–1005 |year=2009 |month=July |pmid=19417585 |doi=10.1097/PAS.0b013e3181a02d1c |url=}}</ref> | ||
*Can be subclassified into four groups - as per Stanford. | *Can be subclassified into four groups - as per Stanford. | ||
Management: | Management: | ||
| Line 22: | Line 23: | ||
*p16 +ve. | *p16 +ve. | ||
*p53 +ve. | *p53 +ve. | ||
==See also== | ==See also== | ||
| Line 28: | Line 28: | ||
==References== | ==References== | ||
{{Reflist| | {{Reflist|1}} | ||
[[Category:Genitourinary pathology]] | [[Category:Genitourinary pathology]] | ||
[[Category:Gynecologic pathology]] | [[Category:Gynecologic pathology]] | ||
[[Category:Diagnosis]] | [[Category:Diagnosis]] | ||